ReviewAnaerobe2013
A clinical and epidemiological review of non-toxigenic Clostridium difficile.
Review in Anaerobe, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 68 citations in OpenAlex.
- Bacterial probiotics as an aid in the control of Clostridium difficile disease in neonatal pigs.The Canadian veterinary journal = La revue veterinaire canadienne · 2016Trial
- Clostridioides difficile in West Africa: a systematic review of the limited evidence and key knowledge gaps.Global epidemiology · 2026Article
- Characterization of the clade 4 non-toxigenicFEMS microbes · 2026Article
- Performance evaluation of the QIAstat-Dx gastrointestinal panel 2 for the detection ofJournal of clinical microbiology · 2025Article
- Review
- Update on Commonly Used Molecular Typing Methods forMicroorganisms · 2023Review
- Genomic Analysis ofMicroorganisms · 2023Article
- A local-scale One Health genomic surveillance ofMicrobial genomics · 2023Article
- Capturing the environment of the Clostridioides difficile infection cycle.Nature reviews. Gastroenterology & hepatology · 2022Review
- Development of an Effective Nontoxigenic Clostridioides difficile-Based Oral Vaccine against C. difficile Infection.Microbiology spectrum · 2022Article
- Towards Development of a Non-ToxigenicPharmaceutics · 2022Article
- Genomic and Phenotypic Characterization of the Nontoxigenic Clostridioides difficile Strain CCUG37785 and Demonstration of Its Therapeutic Potential for the Prevention of C. difficile Infection.Microbiology spectrum · 2022Article
- Clostridioides difficile infection and One Health: an equine perspective.Environmental microbiology · 2022Review
- Application of recombinant antibodies for treatment ofFrontiers in immunology · 2022Review
- Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy.Frontiers in cellular and infection microbiology · 2021Review
- Detection and elimination of a novel non-toxigenicGut microbes · 2020Article
- Evaluation of glutamate dehydrogenase (GDH) and toxin A/B rapid tests for Clostridioides (prev. Clostridium) difficile diagnosis in a university hospital in Minas Gerais, Brazil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2020Article
- High Resolution Melt Assays to Detect and IdentifyMicroorganisms · 2020Article
- Prevalence and antimicrobial susceptibility pattern of toxigenic Clostridium difficilestrains isolated in IranTurkish journal of medical sciences · 2019Article
- Phenotypic Characterization of Non-toxigenicFrontiers in microbiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Clostridium difficile is a significant nosocomial threat to human health and is the most commonly identified cause of antibiotic-associated diarrhea. The development of C. difficile colitis requires production of toxins A and/or B, but some strains do not express these proteins. These non-toxigenic C. difficile (NTCD) have garnered attention for their capacity to colonize humans and potentially reduce the risk for symptomatic colitis caused by toxigenic strains. Isolates of NTCD have been obtained from the environment as well as from animal and human sources. Studies in a hamster CDI model have demonstrated a protective effect of NTCD against toxigenic infection. The extent to which this protective effect of NTCD occurs in humans remains to be defined. Evidence for a therapeutic or preventive role for NTCD is limited but clinical prophylaxis studies are ongoing. NTCD potentially represents an exciting new tool in preventing CDI and its recurrences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.